Zobrazeno 1 - 10
of 644
pro vyhledávání: '"Adam Brufsky"'
Autor:
Alexandra R. Harris, Tengteng Wang, Yujing J. Heng, Gabrielle M. Baker, Phuong Anh Le, Jun Wang, Christine Ambrosone, Adam Brufsky, Fergus J. Couch, Francesmary Modugno, Christopher G. Scott, Celine M. Vachon, Susan E. Hankinson, Bernard A. Rosner, Rulla M. Tamimi, Cheng Peng, A. Heather Eliassen
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-14 (2024)
Abstract Background Early menarche is an established risk factor for breast cancer but its molecular contribution to tumor biology and prognosis remains unclear. Methods We profiled transcriptome-wide gene expression in breast tumors (N = 846) and tu
Externí odkaz:
https://doaj.org/article/76b5bacfbc8949afa92769f09a2daa34
Autor:
Julia Foldi, Anastasia Tsagianni, Max Salganik, Catherine A. Schnabel, Adam Brufsky, G. J. van Londen, Lajos Pusztai, Tara Sanft
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Purpose Extending adjuvant endocrine therapy (ET) beyond the standard 5 years offers added protection against late breast cancer recurrences in women with early-stage hormone receptor-positive (HR +) breast cancer. Little is known about trea
Externí odkaz:
https://doaj.org/article/f5c0edec0ade4ca3949ccb86ca900bd9
Publikováno v:
Breast, Vol 69, Iss , Pp 375-381 (2023)
Background: Palbociclib, the first available cyclin-dependent kinase 4/6 inhibitor, plus endocrine therapy is approved for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC). This
Externí odkaz:
https://doaj.org/article/1760d8d1336f40408af6483302b80b8e
Autor:
Nicole O. Williams, Dionisia Quiroga, Courtney Johnson, Adam Brufsky, Mara Chambers, Saveri Bhattacharya, Maria Patterson, Sagar D. Sardesai, Daniel Stover, Maryam Lustberg, Anne M. Noonan, Mathew Cherian, Darlene M. Bystry, Kasey L. Hill, Min Chen, Mitch A. Phelps, Michael Grever, Julie A. Stephens, Bhuvaneswari Ramaswamy, William E. Carson, Robert Wesolowski
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Heat shock protein 90 (HSP90) is a molecular chaperone required for stabilization of client proteins over-activated in triple-negative breast cancer (TNBC). Over-expression of HSP90 client proteins has been implicated in paclitaxel resist
Externí odkaz:
https://doaj.org/article/c53632218637477c91145bbc4eb4d598
Autor:
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Hope S. Rugo
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundElderly patients are generally underrepresented in oncology clinical trials; therefore, real-world data are needed to inform clinical management of elderly patients with hormone receptor–positive/human epidermal growth factor receptor 2
Externí odkaz:
https://doaj.org/article/e1bd7ccab11141abb188b9e3f60b8819
Autor:
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, A. Jo Chien, Hope S. Rugo, Adam Brufsky, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A. García-Sáenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A. Cheong, Benjamin Schnappauf, Dieter Semsek, Christian F. Singer, Navid Foruzan, Daniel DiPrimeo, Leanne McCulloch, Sara A. Hurvitz, Carlos H. Barcenas
Publikováno v:
Breast, Vol 67, Iss , Pp 94-101 (2023)
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea is the most frequent side effect and the most common reason for early discontinuation. The phase
Externí odkaz:
https://doaj.org/article/59dce946fa4342e6b9fbbf464f2e5a40
Autor:
Foluso O. Ademuyiwa, Feng Gao, Cherease R. Street, Ina Chen, Donald W. Northfelt, Robert Wesolowski, Mili Arora, Adam Brufsky, E. Claire Dees, Cesar A. Santa-Maria, Roisin M. Connolly, Jeremy Force, Alvaro Moreno-Aspitia, John M. Herndon, Madelyn Carmody, Sherri R. Davies, Sarah Larson, Kathleen L. Pfaff, Stephanie M. Jones, Jason L. Weirather, Anita Giobbie-Hurder, Scott J. Rodig, Zheng Liu, Ian S. Hagemann, Elad Sharon, William E. Gillanders
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-11 (2022)
Abstract Atezolizumab with chemotherapy has shown improved progression-free and overall survival in patients with metastatic PD-L1 positive triple negative breast cancer (TNBC). Atezolizumab with anthracycline- and taxane-based neoadjuvant chemothera
Externí odkaz:
https://doaj.org/article/d2b06f8f41a040519a09fe040f35b01e
Autor:
Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-13 (2022)
Abstract Data on real-world effectiveness of cyclin-dependent kinase 4/6 inhibitor combination therapy versus endocrine therapy alone are limited. The Flatiron Health Analytic Database was used to assess overall survival (OS) in patients with hormone
Externí odkaz:
https://doaj.org/article/532b070bf1404214b28d22f57d839c91
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCyclin-dependent kinase 4/6 inhibitors are a standard treatment for patients with hormone receptor−positive (HR+)/human epidermal growth factor receptor 2−negative (HER2−) metastatic breast cancer (MBC). However, real-world data on ef
Externí odkaz:
https://doaj.org/article/ad5cffb6e1d8458096a01ecd1cd72959
Autor:
Angela DeMichele, Massimo Cristofanilli, Adam Brufsky, Xianchen Liu, Jack Mardekian, Lynn McRoy, Rachel M. Layman, Birol Emir, Mylin A. Torres, Hope S. Rugo, Richard S. Finn
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-10 (2021)
Abstract Background Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on
Externí odkaz:
https://doaj.org/article/ffd7b19aa36e4377b6f02a192829a6e4